<div id="readability-page-1"><div>NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against RxSight, Inc. (“RxSight” or the “Company”)(NASDAQ: RXST). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether RxSight and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until September 22, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired RxSight securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com. [Click here for information about joining the class action] On July 8, 2025, RxSight reported preliminary second quarter 2025 financial results, revealing significant declines in Light Delivery Device (“LDD”) sales, light adjustable intraocular lenses utilization, and overall revenue. The Company also lowered its full year 2025 guidance by approximately $42.5 million at the midpoint. RxSight’s Chief Executive Officer, Ronald Kurtz, disclosed that “[a] doption challenges over the last few quarters have been a primary reason for the LDD stall.” On this news, RxSight’s stock price fell $4.84 per share, or 37.84%, to close at $7.95 per share on July 9, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: Danielle Peyton Pomerantz LLP dpeyton@pomlaw.com 646-581-9980 ext. 7980 <img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVd09ESXpOeU0zTURnM056a3lJekl3TVRjMk5EUT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVd09ESXpOeU0zTURnM056a3lJekl3TVRjMk5EUT0"/> <img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2M2YWVkZmItYWE3My00MzY3LWJmNjItMjk5NmE5YzYwNGZhLTEwMjkyMTctMjAyNS0wOC0wOS1lbg==/tiny/Pomerantz-LLP.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2M2YWVkZmItYWE3My00MzY3LWJmNjItMjk5NmE5YzYwNGZhLTEwMjkyMTctMjAyNS0wOC0wOS1lbg==/tiny/Pomerantz-LLP.png"/></div></div>

RXST

Pomerantz 律师事务所已对 RxSight, Inc.（纳斯达克代码：RXST）提起集体诉讼，指控其涉嫌证券欺诈。遭受损失的投资者被鼓励在 2025 年 9 月 22 日之前联系该事务所，以申请成为首席原告。此次诉讼是由于 RxSight 在 2025 年第二季度的业绩令人失望，销售额大幅下降，全年指导预期减少 4250 万美元，导致股价下跌 37.84%。Pomerantz LLP 专注于公司和证券集体诉讼

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in RxSight, Inc. of Class Action Lawsuit and Upcoming Deadlines - RXST

投资者警示：Pomerantz 律师事务所提醒在 RxSight, Inc.投资中遭受损失的投资者注意集体诉讼及即将到来的截止日期 - RXST